(a) The executive commissioner may establish a controlled substance therapeutic research program for the supervised use of tetrahydrocannabinols for medical and research purposes to be conducted in accordance with this chapter.
(b) If the executive commissioner establishes the program, the executive commissioner shall create a research program review board. The review board members are appointed by the executive commissioner and serve at the will of the executive commissioner.

(c) The review board shall be composed of:
(1) a licensed physician certified by the American Board of Ophthalmology;
(2) a licensed physician certified by the American Board of Internal Medicine and certified in the subspecialty of medical oncology;
(3) a licensed physician certified by the American Board of Psychiatry;
(4) a licensed physician certified by the American Board of Surgery;
(5) a licensed physician certified by the American Board of Radiology; and
(6) a licensed attorney with experience in law pertaining to the practice of medicine.
(d) Members serve without compensation but are entitled to reimbursement for actual and necessary expenses incurred in performing official duties.